Raxone
idebenone · Chiesi Farmaceutici S.p.A
EXCEPTIONAL CIRCUMSTANCES AUTHORISED IN THE EUWhat Raxone is used for
Raxone is indicated for the treatment of visual impairment in adolescent and adult patients with Leber’s Hereditary Optic Neuropathy (LHON).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Approved under exceptional circumstances: full data cannot be collected, usually because the disease is very rare.
Key facts
- Brand
- Raxone
- Active substance
- idebenone
- Disease area
- Optic Atrophy, Hereditary, Leber
- Medicine group
- Psychoanaleptics;Other psychostimulants and nootropics
- ATC code
- N06BX13
- Marketing authorisation holder
- Chiesi Farmaceutici S.p.A
- Authorised in the EU since
- 2015
Official information
In India
- Idebenone: 7 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Raxone used for?
Raxone is indicated for the treatment of visual impairment in adolescent and adult patients with Leber’s Hereditary Optic Neuropathy (LHON).
What is the active substance in Raxone?
Raxone contains idebenone.
Who makes Raxone?
The EU marketing authorisation holder is Chiesi Farmaceutici S.p.A.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU